


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**INNOVATIVE MEDICINE “F-627 (EFBEMALENOGRASTIM ALFA INJECTION)”**  
**APPROVED FOR MARKETING**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Category 1 innovative medicine “F-627 (Efbemalenograstim alfa Injection)” (marketed as Yilishu (億立舒) in China) jointly developed by the Group was approved for marketing by the National Medical Products Administration of China for the prevention and treatment of neutropenia in oncology patients after receiving chemotherapy drugs.

Neutropenia (CIN) is a common side effect of chemotherapy drugs for the treatment of tumors. It is a condition in which the level of neutrophils (a type of white blood cells which protect against infection) remain low due to the use of chemotherapy drugs, thus increasing the risk of infection and fever in cancer patients during chemotherapy. Yilishu is a new generation of long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursors and the release of mature neutrophils, thereby enhancing the immune system of cancer patients, preventing the side effects of chemotherapy-induced neutropenia in cancer patients, and avoiding the resultant reduction in the dose of chemotherapy drugs or delay in their administration, which may affect the effectiveness of tumor treatment.

This approval is based on three pivotal Phase III trials completed worldwide in a multicenter, randomized and controlled study comparing the efficacy and safety of Yilishu with Neupogen, a short-acting drug which boosts white blood cells, and Neulasta, a long-acting drug which boosts white blood cells, which are commonly used in clinical settings. The results of the trials demonstrated the efficacy and safety of Yilishu and its benefits in terms of innovative mechanisms.

As a third-generation long-acting G-CSF, Yilishu has the significant advantages of high stability and low immunogenicity, allowing earlier dosing and better treatment compliance for patients. Its launch will further facilitate the development of the long-acting G-CSF market in China, benefit cancer patients and promote their family well-being.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 9 May 2023

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*